-
US faces tough path to new Iran nuclear deal
-
Good US Open shots not good enough for 2-over Scheffler
-
Cuba unveils historic package of free-market reforms
-
Subs send Swiss to World Cup rout of Bosnia-Herzegovina
-
Stokes set for England return in New Zealand finale - reports
-
McIlroy pleased with reduced green speeds in US Open winds
-
Quarantine over for almost all hantavirus ship passengers, crew
-
US stocks resume upward climb as dollar advances again after Fed outlook
-
Ex-presidents and stars, but no Trump, turn out for Obama Library
-
Stevens seizes US Open lead with McIlroy, Aberg one back
-
Al-Qaeda-linked jihadists attack Niger airport, 11 soldiers killed
-
'Big-game' Bellingham shows his worth for England at World Cup
-
New Zealand's Henry rocks England in 2nd Test after Phillips century
-
Vance warns Israel against criticizing US-Iran deal
-
Iran's supreme leader says approved deal as US lifts ports blockade
-
Australian qualifier Hijikata shocks Lehecka at Queen's Club
-
AI-generated videos use Down syndrome to make sales
-
O'Brien's royal century reward for sacrificing all for racing
-
Spurs sign Dutch defender Van Hecke from Brighton
-
England great Botham slams Stokes for breaking curfew
-
Liverpool agree deal to sign Spain forward Munoz from Osasuna
-
Chivu extends Inter deal until 2028 after debut season double triumph
-
New Zealand's Henry rocks England after Phillips century
-
Ghana pushes for concrete slavery reparations
-
Wildcard Eala shocks Rybakina in Berlin
-
Robertson and Scotland eye World Cup history against Morocco
-
South Africa hold Czechs, keep World Cup knockout dream alive
-
Joyful New York celebrates Knicks with ticker-tape parade
-
Important or selfish? World Cup evidence mounts against Ronaldo
-
Europe risks 'total irrelevance' without sovereign tech: Cohere chief
-
EU wrestles over tackling China export flood
-
Ex-presidents, stars, but no Trump, turn out for Obama Center
-
Vance defends Iran deal, eyes Swiss talks
-
US Olympic athlete Simpson shows 'improvement' after collasing on track
-
Wahi granted Canadian visa for Ivory Coast World Cup match after delay
-
Israel FM cuts contact with EU top diplomat over 'apartheid' remarks
-
US lifts Iran ports blockade as uncertainty clouds Swiss Iran talks
-
Brazilian police probe senator close to Lula
-
Brutal Shinnecock winds blow away US Open contenders
-
Leverkusen sign Portuguese talent Moreira from Lyon
-
AI-generated videos wield Down syndrome to make sales
-
Suspected jihadists stage deadly new attack on Niger airport
-
Man dies, trains and classes disrupted as heatwave hits France
-
Oil sinks on Mideast deal, but Fed outlook knocks equities
-
Neymar to miss Brazil's second World Cup game against Haiti
-
Dupont to start for Toulouse in Top 14 semi, Ramos out
-
O'Brien's historic 100th Royal Ascot winner has golden glow
-
Zverev wins all-German duel with Hanfmann to reach Halle quarters
-
Graft probe into Spanish ex-PM expanded to daughters
-
Iran war leaves Islamic republic intact and opponents divided
US greenlights pig kidney transplant trials
Two US biotech companies say the Food and Drug Administration has cleared them to conduct clinical trials of their gene-edited pig kidneys for human transplants.
United Therapeutics along with another company, eGenesis, have been working since 2021 on experiments implanting pig kidneys into humans: initially brain-dead patients and more recently living recipients.
Advocates hope the approach will help address the severe organ shortage. More than 100,000 people in the United States are awaiting transplants, including over 90,000 in need of kidneys.
United Therapeutics's approval, announced Monday, allows the company to advance its technology toward a licensed product if the trial succeeds.
The study authorization was hailed as a "significant step forward in our relentless mission to expand the availability of transplantable organs," by Leigh Peterson, the company's executive vice president.
The trial will initially enroll six patients with end-stage renal disease before expanding to as many as 50, United Therapeutics said in a statement. The first transplant is expected in mid-2025.
Meanwhile, rival eGenesis said it had received FDA approval in December for a separate three-patient kidney study.
"The study will evaluate patients with kidney failure who are listed for a transplant but who face a low probability of receiving a deceased donor offer within a five-year timeframe," the company said.
Xenotransplantation -- transplanting organs from one species to another -- has been a tantalizing yet elusive goal for science.
Early experiments in primates faltered, but advances in gene editing and immune system management have brought the field closer to reality.
Pigs have emerged as ideal donors: they grow quickly, produce large litters, and are already part of the human food supply.
United Therapeutics said trial patients would be monitored for life, assessing survival rates, kidney function, and the risk of zoonotic infections -- diseases that jump from animals to humans.
Currently, there is only one living human recipient of a pig organ: Towana Looney, a 53-year-old from Alabama who received a United Therapeutics kidney on November 25, 2024.
She is also the longest-surviving recipient, having lived with a pig kidney for 71 days as of Tuesday. David Bennett of Maryland received a pig heart in 2022 and survived 60 days.
K.Sutter--VB